Former CEO resigns from Molecular Insight board

TriMed Staff | | Health Imaging | Cardiac Imaging
David S. Barlow has resigned from the board of directors of Molecular Insight Pharmaceuticals, a Cambridge, Mass.-based developer of radiotherapeutics and molecular imaging agents in oncology and cardiology.

The resignation went into effect Dec. 30, 2008 and was related to Barlow’s “disagreements with the board,” he said in a statement.

Barlow is the former CEO of Molecular Insight. In September 2008, the company announced that Barlow would immediately be replaced by interim CEO and chairman of the board John Babich, who formerly served as president and chief scientific officer of Molecular Insight before taking the helm.

TriMed Staff

Related Content

Global shortage of nuclear imaging isotopes may be over
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
FDA clears AI tool that flags signs of heart disease in chest CT scans
AI-enabled plaque assessments help cardiologists ID high-risk CAD patients
Abbott CGM sensors can now be worn during common imaging procedures
New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup